Small molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in the other

Immunity

Volumn 19, Issue 3, 2003, Pages 391-402

  Shimaoka, Motomu ^a   Salas, Azucena ^a   Yang, Wei ^a   Weitz Schmidt, Gabriele ^b   Springer, Timothy A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

A 286982; BETA2 INTEGRIN; BIRT 377; CD11B ANTIGEN; INTEGRIN; INTEGRIN ANTAGONIST; LFA 703; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROTEIN INHIBITOR; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; XVA 143;

ALPHA CHAIN; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BETA CHAIN; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CONFORMATION; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0141746138     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(03)00238-3     Document Type: Article

References (58)

1. Alonso J.L., Essafi M., Xiong J.P., Stehle T., Arnaout M.A. Does the integrin αA domain act as a ligand for its βA domain? Curr. Biol. 12:2002;R340-R342.
2. Anderson D.C., Smith C.W., Springer T.A. Leukocyte adhesion deficiency and other disorders of leukocyte motility. Stanbury J.B., Wyngaarden J.B., Frederickson D.S. Metabolic Basis of Inherited Disease. 1989;McGraw-Hill, New York. 2751-2777.pp.
3. Beglova N., Blacklow S.C., Takagi J., Springer T.A. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat. Struct. Biol. 9:2002;282-287.
4. Burdick, D.J. (1999). Genentech, USA. Oct 7. Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders. PCT Int. Appl. WO9949856.
5. Burdick, D.J., Gadek, T.R., Marsters, J., Oare, D.A., Reynolds, M.E., and Stanley, M.S. (2001). Nov 26. LFA-1 Antagonist Compounds. PCT Int. Appl. WO02059114.
6. de Fougerolles A.R., Sprague A.G., Nickerson-Nutter C.L., Chi-Rosso G., Rennert P.D., Gardner H., Gotwals P.J., Lobb R.R., Koteliansky V.E. Regulation of inflammation by collagen-binding integrins α1β1 and alpha2beta1 in models of hypersensitivity and arthritis. J. Clin. Invest. 105:2000;721-729.
7. Dransfield I., Hogg N. Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits. EMBO J. 8:1989;3759-3765.
8. Du X., Plow E.F., Frelinger A.L. III, O'Toole T.E., Loftus J.C., Ginsberg M.H. Ligands "activate" integrin αIIbβ3 (platelet GPIIb-IIIa). Cell. 65:1991;409-416.
9. Dustin M.L., Carpen O., Springer T.A. Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 adhesion receptors. J. Immunol. 148:1992;2654-2663.
10. Fotouhi, N., Gillespie, P., Guthrie, R., Pietranico-Cole, S., and Yun, W. Hoffmann-La Roche, Switzerland. (1999). Oct 12. Diaminopropionic acid derivatives. PCT Int. Appl. WO0021920.
11. Fotouhi, N., Gillespie, P., Guthrie, R., Pietranico-Cole, S., and Yun, W.F. Hoffman-LaRoche, USA. (2001). Feb 1. Dehydroamino acids. PCT Int. Appl. WO0158853.
12. Gadek T.R., Burdick D.J., McDowell R.S., Stanley M.S., Marsters J.C. Jr., Paris K.J., Oare D.A., Reynolds M.E., Ladner C., Zioncheck K.A.et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 295:2002;1086-1089.
13. 2-integrins and their cellular ligands Eur. J. Biochem. 245:1997;215-232.
14. Gottlieb A.B., Bos J.D. Recombinantly engineered human proteins. transforming the treatment of psoriasis Clin. Immunol. 105:2002;105-116.
15. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., Garovoy M. Psoriasis as a model for T-cell-mediated disease. immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody Arch. Dermatol. 138:2002;591-600.
16. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L. The immunological synapse. a molecular machine controlling T cell activation Science. 285:1999;221-227.
17. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., Schuler W., Schulz M., Werner F.J., Winiski A.et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases. in vitro pharmacology Br. J. Dermatol. 141:1999;264-273.
18. Harlan J.M., Winn R.K., Vedder N.B., Doerschuk C.M., Rice C.L. In vivo models of leukocyte adherence to endothelium. Harlan J.R., Liu D. Adhesion. Its Role in Inflammatory Disease:1992;W.H. Freeman & Company, New York. 117-150.pp.
19. Harris E.S., McIntyre T.M., Prescott S.M., Zimmerman G.A. The leukocyte integrins. J. Biol. Chem. 275:2000;23409-23412.
20. Huang C., Springer T.A. A binding interface on the I domain of lymphocyte function associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J. Biol. Chem. 270:1995;19008-19016.
21. Huang C., Zang Q., Takagi J., Springer T.A. Structural and functional studies with antibodies to the integrin β2 subunit. a model for the I-like domain J. Biol. Chem. 275:2000;21514-21524.
22. Huth J.R., Olejniczak E.T., Mendoza R., Liang H., Harris E.A., Lupher M.L. Jr., Wilson A.E., Fesik S.W., Staunton D.E. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc. Natl. Acad. Sci. USA. 97:2000;5231-5236.
23. Jackson D.Y. α4 integrin antagonists. Curr. Pharm. Des. 8:2002;1229-1253.
24. Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., Cottens S., Weitz-Schmidt G., Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292:1999;1-9.
25. Last-Barney K., Davidson W., Cardozo M., Frye L.L., Grygon C.A., Hopkins J.L., Jeanfavre D.D., Pav S., Qian C., Stevenson J.M.et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies. evidence for the allosteric inhibition of a protein-protein interaction J. Am. Chem. Soc. 123:2001;5643-5650.
26. Lee J.-O., Rieu P., Arnaout M.A., Liddington R. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell. 80:1995;631-638.
27. Leitinger B., Hogg N. Effects of I domain deletion on the function of the β2 integrin lymphocyte function-associated antigen-1. Mol. Biol. Cell. 11:2000;677-690.
28. Liu G., Huth J.R., Olejniczak E.T., Mendoza R., DeVries P., Leitza S., Reilly E.B., Okasinski G.F., Fesik S.W., von Geldern T.W. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. 44:2001;1202-1210.
29. Lu C., Springer T.A. The α subunit cytoplasmic domain regulates the assembly and adhesiveness of integrin lymphocyte function-associated antigen-1 (LFA-1). J. Immunol. 159:1997;268-278.
30. Lu C., Ferzly M., Takagi J., Springer T.A. Epitope mapping of antibodies to the C-terminal region of the integrin β2 subunit reveals regions that become exposed upon receptor activation. J. Immunol. 166:2001;5629-5637. a.
31. Lu C., Shimaoka M., Ferzly M., Oxvig C., Takagi J., Springer T.A. An isolated, surface-expressed I domain of the integrin αLβ2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide. Proc. Natl. Acad. Sci. USA. 98:2001;2387-2392. b.
32. Lu C., Shimaoka M., Zang Q., Takagi J., Springer T.A. Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc. Natl. Acad. Sci. USA. 98:2001;2393-2398. c.
33. Martin S., Casasnovas J.M., Staunton D.E., Springer T.A. Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J. Virol. 67:1993;3561-3568.
34. Nicolls M.R., Coulombe M., Beilke J., Gelhaus H.C., Gill R.G. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J. Immunol. 169:2002;4831-4839.
35. Peter K., Schwarz M., Nordt T., Bode C. Intrinsic activating properties of GP IIb/IIIa blockers. Thromb. Res. Suppl. 103:2001;S21-S27.
36. Petruzzelli L., Maduzia L., Springer T.A. Activation of LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18. J. Immunol. 155:1995;854-866.
37. Poston R.S., Robbins R.C., Chan B., Simms P., Presta L., Jardieu P., Morris R.E. Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation. 69:2000;2005-2013.
38. Salas A., Shimaoka M., Chen S., Carman C.V., Springer T.A. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin LFA-1. J. Biol. Chem. 277:2002;50255-50262.
39. Sarnacki S., Auber F., Cretolle C., Camby C., Cavazzana-Calvo M., Muller W., Wagner N., Brousse N., Revillon Y., Fischer A., Cerf-Bensussan N. Blockade of the integrin alphaLbeta2 but not of integrins α4 and/or β7 significantly prolongs intestinal allograft survival in mice. Gut. 47:2000;97-104.
40. Shimaoka M., Shifman J.M., Jing H., Takagi J., Mayo S.L., Springer T.A. Computational design of an integrin I domain stabilized in the open, high affinity conformation. Nat. Struct. Biol. 7:2000;674-678.
41. Shimaoka M., Lu C., Palframan R., von Andrian U.H., Takagi J., Springer T.A. Reversibly locking a protein fold in an active conformation with a disulfide bond. integrin αL I domains with high affinity and antagonist activity in vivo Proc. Natl. Acad. Sci. USA. 98:2001;6009-6014.
42. Shimaoka M., Takagi J., Springer T.A. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 31:2002;485-516.
43. Shimaoka M., Xiao T., Liu J.-H., Yang Y., Dong Y., Jun C.-D., McCormack A., Zhang R., Joachimiak A., Takagi J.et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 112:2003;99-111.
44. Springer T.A. Adhesion receptors of the immune system. Nature. 346:1990;425-433.
45. Springer T.A. Predicted and experimental structures of integrins and β-propellers. Curr. Opin. Struct. Biol. 12:2002;802-813.
46. Takagi J., Springer T.A. Integrin activation and structural rearrangement. Immunol. Rev. 186:2002;141-163.
47. Takagi J., Erickson H.P., Springer T.A. C-terminal opening mimics "inside-out" activation of integrin α5β1. Nat. Struct. Biol. 8:2001;412-416.
48. Takagi J., Petre B.M., Walz T., Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 110:2002;599-611.
49. Thibault G. Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins. a novel approach to study integrins Mol. Pharmacol. 58:2000;1137-1145.
50. van Kooyk Y., Weder P., Hogervorst F., Verhoeven A.J., van Seventer G., te Velde A.A., Borst J., Keizer G.D., Figdor C.G. Activation of LFA-1 through a Ca2+-dependent epitope stimulates lymphocyte adhesion. J. Cell Biol. 112:1991;345-354.
51. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:2001;687-692.
52. Welzenbach K., Hommel U., Weitz-Schmidt G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. molecular insights into integrin inhibition J. Biol. Chem. 277:2002;10590-10598.
53. Woska J.R. Jr., Shih D., Taqueti V.R., Hogg N., Kelly T.A., Kishimoto T.K. A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J. Leukoc. Biol. 70:2001;329-334.
54. Xiong J.-P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., Joachimiak A., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin αVβ3. Science. 294:2001;339-345.
55. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science. 296:2002;151-155.
56. Yalamanchili P., Lu C., Oxvig C., Springer T.A. Folding and function of I-domain deleted Mac-1 and LFA-1. J. Biol. Chem. 275:2000;21877-21882.
57. Zang Q., Lu C., Huang C., Takagi J., Springer T.A. The top of the I-like domain of the integrin LFA-1 β subunit contacts the α subunit β-propeller domain near β-sheet 3. J. Biol. Chem. 275:2000; 22202-22212.
58. Zolotarjova N.I., Hollis G.F., Wynn R. Unusually stable and long-lived ligand-induced conformations of integrins. J. Biol. Chem. 276:2001;17063-17068.